Stock Yards Bank & Trust Co. Has $5.92 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Stock Yards Bank & Trust Co. cut its position in Amgen Inc. (NASDAQ:AMGN) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,554 shares of the medical research company’s stock after selling 106 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Amgen were worth $5,920,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth $4,589,900,000. Assenagon Asset Management S.A. raised its holdings in shares of Amgen by 486.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock worth $258,997,000 after acquiring an additional 745,929 shares during the period. abrdn plc raised its holdings in shares of Amgen by 150.4% during the fourth quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock worth $300,580,000 after acquiring an additional 626,810 shares during the period. Royal Bank of Canada raised its holdings in shares of Amgen by 11.4% during the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock worth $1,365,213,000 after acquiring an additional 518,689 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Amgen during the third quarter worth $128,425,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $3.70 during mid-day trading on Monday, reaching $272.63. 780,994 shares of the company were exchanged, compared to its average volume of 2,831,551. The company’s 50-day simple moving average is $276.90 and its 200-day simple moving average is $281.51. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $146.23 billion, a P/E ratio of 21.53, a P/E/G ratio of 2.50 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter last year, the company posted $4.09 EPS. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $329.00 price objective on shares of Amgen in a report on Wednesday, April 3rd. TD Cowen decreased their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $296.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.